藥明巨諾(02126.HK)治療大B細胞淋巴瘤藥物 隨訪數據顯示可爲患者帶來持續緩解
藥明巨諾(02126.HK)公佈,瑞基奧侖賽注射液(研發代號:JWCAR029)治療經過二線或以上系統性治療後成人患者的復發或難治性(r/r)大B細胞淋巴瘤(LBCL)(RELIANCE研究)的一年隨訪數據。
藥明巨諾首席醫學官Mark Gilbert表示,大B細胞淋巴瘤是最常見及最具侵襲性的非霍奇金淋巴瘤,許多患者在初始治療後復發,標準治療選擇有限且中位生存大約爲6個月。RELIANCE研究的長期隨訪數據表明,瑞基奧侖賽注射液爲患者帶來了持續緩解,代表着一種潛在的重要治療選擇,爲這些患者提供了更長的生存期的明確希望。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.